According to a recent LinkedIn post from HistoSonics, the company is promoting a live webinar focused on the clinical and economic impact of its histotripsy technology for patients with limited treatment options. The session, scheduled for Thursday, March 26, will feature surgeons from Cleveland Clinic and Cooper University, and will be moderated by HistoSonics’ medical director.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights an agenda covering histotripsy’s mechanism of action, clinical utilization, emerging evidence, and ongoing clinical trials and research, along with program-level economic considerations. For investors, the emphasis on economic impact and practice integration suggests HistoSonics is working to position histotripsy as a viable, revenue-generating modality for providers, which could support future adoption and reimbursement prospects.
Featuring recognized clinical specialists from major institutions may help build external validation and awareness in the surgical oncology community. If the webinar effectively demonstrates both clinical value and favorable economics, it could strengthen HistoSonics’ competitive position in image-guided and minimally invasive oncology treatments and support longer-term commercialization of its Edison System, currently limited outside liver applications to clinical investigations.